CLINICAL EVALUATION FENUGREEK SEED EXTRACT IN PATIENTS WITH TYPE-2 DIABETES: AN ADD-ON STUDY IN 154 PATIENTS
Prof. Narsingh Verma*, Dr. Kauser Usman, Vandana Awasthi, Pawan K Goel, Gopesh Lamgora
ABSTRACT
Diabetes is an epidemic disease and is considered as the major cause of
mortality and morbidity across globe. The global increase in the
prevalence of diabetes is due to the combination of causes such as
population growth, aging, unplanned fast urbanization and an increase
in obesity and physical inactivity. Addition of fenugreek seed extract
in the diet may reduce blood sugar and urine sugar levels along with
improvement in glucose tolerance in type-2 diabetic patients. The
present study was an add-on, randomized, double blind, placebo
controlled study to evaluate the efficacy and safety of the standardized
fenugreek seed extract as furostenolic saponins. It included the oral
administration of Fenugreek seed extract (Fenfuro) in 154 patients suffering from type-2
diabetes mellitus were randomized in two groups. One group of patients received Fenfuro and
the other group received Placebo. The subjects were assed clinically and biochemically at
pre-defined intervals of 4 weeks during 12 weeks study. Fenfuro effectively caused
significant change in blood glucose levels, decrease in HbA1c levels, fasting plasma glucose
levels, PP plasma glucose levels and increase in C-peptide levels as compared to Placebo
group. Fenfuro-treated group also showed reduction in concomitant anti-diabetic therapy.
This fenugreek preparation was also found to be safe in patients with type-2 diabetes as
depicted by the safety parameters.
Keywords: furostenolic saponins, (Fenfuro).
[Full Text Article]